Synergistic effect of gefitinib and rofecoxib in mesothelioma cells

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Stoppoloni, Daniela ^a   Canino, Claudia ^a   Cardillo, Irene ^a   Verdina, Alessandra ^a   Baldi, Alfonso ^b   Sacchi, Ada ^a   Galati, Rossella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; ROFECOXIB; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; LACTONE; PTGS2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; SULFONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL KILLING; CELL SPECIFICITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MESOTHELIOMA; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLOOXYGENASE 2; DRUG SYNERGISM; HUMANS; LACTONES; MESOTHELIOMA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SULFONES;

EID: 77649105754     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-27     Document Type: Article

References (36)

1. Peto J, Decaril A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999, 79:666-672. 10.1038/sj.bjc.6690105, 2362439, 10027347.
2. Jackman DM. Current options for systemic therapy in mesothelioma. Semin Thorac Cardiovasc Surg 2009, 21:154-158. 10.1053/j.semtcvs.2009.06.010, 19822287.
3. Cardillo I, Spugnini EP, Verdina A, Galati R, Citro G, Baldi A. COX and mesothelioma, an overview. Histol Histopathol 2005, 20:1267-1274.
4. Baer AN, Green FA. Cyclooxygenase activity of cultured human mesothelial cells. Prostaglandins 1993, 46:37-49. 10.1016/0090-6980(93)90061-B, 8378541.
5. Baldi A, Di Santini D, Vasaturo F, Santini M, Vicidomini G, Di Marino MP, Esposito V, Groeger AM, Liuzzi G, Vincenzi B, Tonini G, Piccoli M, Baldi F, Scarpa S. Prognostic significance of COX-2 and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax 2004, 59:428-433. 10.1136/thx.2003.008912, 1746992, 15115874.
6. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994, 5:138-146. 10.1097/00001648-199403000-00003, 8172988.
7. Spugnini EP, Cardillo I, Verdina A, Crispi S, Saviozzi S, Calogero R, Nebbioso A, Altucci L, Cortese G, Galati R, Chien J, Shridhar V, Vincenzi B, Citro G, Cognetti F, Sacchi A, Baldi A. Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res 2006, 12:6133-6143. 10.1158/1078-0432.CCR-06-1056, 17062690.
8. Verdina A, Cardillo I, Nebbioso A, Galati R, Menegozzo S, Altucci L, Sacchi A, Baldi A. Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability. J Transl Med 2008, 22:6-27.
9. Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M, Morrow JD, DuBois RN. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 2003, 19:2195-2199.
10. Mustafa A, Kruger WD. Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer. Clin Cancer Res 2008, 14:4935-4942. 10.1158/1078-0432.CCR-08-0958, 2587271, 18676768.
11. Catalano A, Graciotti L, Rinaldi L, Raffaelli G, Rodilossi S, Betta P, Gianni W, Amoroso S, Procopio A. Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer 2004, 109:322-328. 10.1002/ijc.11710, 14961568.
12. Park W, Oh YY, Han JH, Pyo H. Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis Lung Carcinoma expressing Cyclooxygenase-2. J Exp Clin Cancer Res 2008, 27:66. 10.1186/1756-9966-27-66, 2621123, 19000324.
13. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000, 30:3-21.
14. Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 2002, 62:4903-4908.
15. Choen MS, Zhang X, Shin HJ, Shin DM, Chen ZG. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol CancerTher 2005, 4:1448-455.
16. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7:2958-2970.
17. Dazzi H, Hasleton PS, Thatcher N, Wilkes S, Swindell R, Chatterjee AK. Malignant pleural mesothelioma and epidermal growth factor receptor (EGFR). Relationship of EGF-R with histology and survival using fixed paraffin-embedded tissue and the F4 monoclonal antibody. Br J Cancer 1990, 6:924-926.
18. Faux SP, Houghton CE, Hubbard A, Patrick G. Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres. Carcinogenesis 2000, 21:2275-2280. 10.1093/carcin/21.12.2275, 11133818.
19. Zanella CL, Posada J, Tritton TR, Mossman BT. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res 1996, 56:5334-5338.
20. Rascoe PA, Cao X, Daniel JC, Miller SD, Smythe WR. Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma. J Thorac Cardiovasc Surg 2005, 130:393-400. 10.1016/j.jtcvs.2004.11.029, 16077404.
21. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002, 14:381-95. 10.1016/S0898-6568(01)00271-6, 11882383.
22. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005, 315:971-979. 10.1124/jpet.105.084145, 16002463.
23. Arteaga CL, Ramsey TT, Shawver LK, Guyer CA. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem 1997, 272:23247-23254. 10.1074/jbc.272.37.23247, 9287333.
24. Lichtner RB, Menrad A, Sommer A, Klar U, Schneider MR. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 2001, 61:5790-5795.
25. Nutt JE, O'Toole K, Gonzalez D, Lunec J. Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines. Eur J Cancer 2009, 45:1684-1691. 10.1016/j.ejca.2009.02.022, 19318229.
26. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002, 8:289-293. 10.1038/nm0302-289, 11875501.
27. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005, 23:254-266. 10.1200/JCO.2005.09.112, 15637389.
28. Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, Shin HJ, Chen A, Khuri FR, Shin DM. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005, 11:6261-6269. 10.1158/1078-0432.CCR-04-2102, 16144930.
29. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55. 10.1016/0065-2571(84)90007-4, 6382953.
30. Stoppoloni D, Cardillo I, Verdina A, Vincenzi B, Menegozzo S, Santini M, Sacchi A, Baldi A, Galati R. Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis. Cancer 2008, 113:2761-2769. 10.1002/cncr.23904, 18831511.
31. Jänne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of Epidermal Growth Factor Receptor Signaling in Malignant Pleural Mesothelioma. Cancer Research 2002, 62:5242-5247.
32. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003, 9:2316-2326.
33. Mohiuddin I, Cao X, Ozvaran MK, Zumstein L, Chada S, Smythe WR. Phosphatase and tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of AKT phosphorylation. Ann Surg Oncol 2002, 9:310-316. 10.1007/BF02573071, 11923140.
34. Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, Avallone A, Comella P, Caponigro F, Pepe S, Budillon A. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 2003, 195:139-150. 10.1002/jcp.10239, 12599217.
35. Litvak DA, Papaconstantinou HT, Ko TC, Townsend CM. A novel cytotoxic agent for human carcinoid tumors. Surgery 1998, 124:1071-1076. 10.1067/msy.1998.91830, 9854585.
36. Baldi A, Groeger AM, Esposito V, Cassandro R, Tonini G, Battista T, Di Marino MP, Vincenzi B, Santini M, Angelini A, Rossiello R, Baldi F, Paggi MG. Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival. Thorax 2002, 57:353-356. 10.1136/thorax.57.4.353, 1746306, 11923556.